Results summaries for study participants

We work with regulators to help share clinical trial information with our participants.

As part of our patient focused drug development here at AbbVie, we strive to provide summary information about completed trials in an easy and understandable manner while upholding our commitments to trade associations principles and preparedness for the upcoming European Union (EU) Clinical Trials Regulation requirements.

AbbVie is now publicly disclosing Plain Language Summaries (PLS) of results for clinical trials completed in 2018 for already approved products and or indications. A summary of clinical trial results for laypersons, referred to as a lay summary of results or plain language summary (PLS), is a brief description of the clinical trial results in everyday language that is understandable to people who do not have a medical or scientific background. The set of studies in scope of the 2019 Lay Summary of Results include phase 2-4 studies in approved products and indications.

See below for available summaries:

Hepatitis C

Study ID/Title Condition Description
M16-126
A study to learn how effective and safe a medicine containing glecaprevir and pibrentasvir works to treat adult patients with long-lasting hepatitis-C genotype 5 or 6 infection Hepatitis C virus

Trial dates:
Jan 2017 – Aug 2018

Last modified:
Sep 2019

Available languages:
English

M16-127
A study to learn how well and safe a medicine containing glecaprevir and pibrentasvir works to treat adult patients with long-lasting hepatitis-C infection and kidney damage
Hepatitis C virus

Trial dates:
Mar 2017 – Jun 2018

Last modified:
May 2019

Available languages:
EnglishGerman, Italian, Korean, Polish, Spanish


Psoriasis

Study ID/Title Condition Description
M16-004 
A study to learn how effective and safe a medicine containing the study drug risankizumab works compared to placebo (no medicine) to treat adult Japanese patients with moderate to severe long-lasting plaque psoriasis Psoriasis

Trial dates:
Dec 2016 – Jun 2018

Last modified:
Aug 2019

Available languages:
English, Japanese

M16-009
A study to learn how effective and safe a medicine containing the study drug risankizumab works to treat adult patients with moderate to severe long-lasting plaque psoriasis

Psoriasis

Trial dates:
Nov 2014 – Sep 2018

Last modified:
Jul 2019

Available languages:
EnglishFrenchFrench CanadianGerman

M16-178
A study to learn how effective and safe a medicine containing the study drug risankizumab works compared to the study drug FUMADERM® to treat adult patients with moderate to severe plaque psoriasis Psoriasis

Trial dates:
Aug 2017 – Jul 2018

Last modified:
Jul 2019

Available languages:
EnglishGerman


Uveitis

Study ID/Title Condition Description
M11-327
A study to learn how well and safe
long-term use of a medicine called adalimumab works to treat adult patients with non-infectious intermediate uveitis, posterior uveitis, or panuveitis
Uveitis

Trial dates:
Dec 2010 – May 2018

Last modified:
Jul 2019

Available languages:
English, German, Italian, Japanese, Polish, Spanish